1. Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. и соавт. Стволовые клетки и их применение для регенерации миокарда. Журнал сердечная недостаточность 2003; 4[4): 168-73.
2. Шахов В.П., Попов СВ. Стволовые клетки и кардиомиогенез в норме и патологии. Томск: SST; 2004.
3. Репин B.C., Сухих Г.Т. Медицинская клеточная биология. М.: БЭБиМ; 1998.
4. Бокерия Л.А., Асланиди И.П., Беришвили И.И. и соавт. Непосредственные и отдаленные результаты различных методов хирургического лесения больных с диффузным поражением коронарных артерий. Бюллетень НЦССХ им. А.В.Бакулева РАМН 2004; 5[4): 116-29.
5. Шевченко Ю.Л. Медико-биологические и физиологические основы клеточных технологий в сердечно-сосудистой хирургии. СПб.: Наука; 2006
6. Chachques J.S., Salanson-Lajos С, Lajos С. et al. Cellular cardiomyoplastyfor myocardial regeneration. Asian. Cardiovasc. Thorac. Ann. 2005; 13[3): 287-96.
7. Limbourg F.P., Ringes-Lichtenberg S., Schaefer A. et al. Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment. Eur. J. Heart Fail. 2005; 7[5): 722-9.
8. Katritsis D.G., Sotirapoulou P.A., Karvouni E. et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc. Interv. 2005; 65[3): 321-9.
9. Zhang S., Guo J., Zhang P. et al. Long-term effects of bone marrow mononuclear cell transplantation on left ventricular function and remodeling in rats. Life Sci. 2004; 74[23): 2853-64.
10. Tang Y.L. Autologous mesenchymal stem cells for post-ischemic myocardial repair. Methods Mol. Med. 2005; 112:183-92
11. Матюков А.А.. Влияние йнтрамйокардйальной аутотрансплантацйй клеток костного мозга на перфузию йшемйЗйрованного миокарда в эксперименте. Клеточная трансплантология й тканевая инженерия 2006; 3[5): 42-7.
12. Матюков А.А., Цупкйна Н.В., Власов Т.Д. й др. Сравнение влияния йнтрамйокардйальной аутотрансплантацйй различных клеток костного мозга на репарацию миокарда кроликов после инфаркта. Клеточная трансплантология й тканевая инженерия 2007; Н[1): 48-52.
13. Ромейс Б. Микроскопическая техника. М.: Иностраннаялйтература; 1953.
14. Автэндйлов Г.Г. Медицинская морфометрйя. Руководство. М.: Медицина; 1990.
15. Azamoush К., Maurel A., Sebbah L et. al. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia- inducible factor 1 alpha. J. Thorac. Cardiovasc. Surg. 2005; 130[1): 173-9.
16. Zhang S., Zhang P., Guo J. et al. Enhanced cytoprotection and angiogenesis by bone marrow cell transplantation may contribute to improved ischemic myocardial function. Eur. J. Cardiothorac. Surg. 2004; 25:188-95.
17. Liao Y., Cheng X. Autoimmunity in myocardial infarction. Int. J. Cardiol. 2006:112:21-6.
18. Vandervelde S., Luyn M.J., Tio R.A. et. al. Signaling factors in stem cell- mediated repair of infarcted myocardium. Mol. Cell Cardiol. 2005; 39[2): 363-76
19. Frangogiannis N.G., Entman M.L Chemokines in myocardial ischemia. Trends Cardiovasc. Med. 2005; 15[5): 163-9.
20. Frantz S., Ducharme A., Sawyer D. et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J. Mol. Cell Cardiol. 2003; 35: 685-94
21. Pagani F.D., Baker L.S., Hsi С etal. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J. Clin. Invest. 1992; 90: 389- 98.
22. Ertl G., FrantzS. Healing after myocardial infarction. Cardiovasc. Research 2005:66:22-32.
23. Cheng X., Liao Y.H, Li В., et al. Changes of rat lymphocyte proliferation and cytotoxic activity after acute myocardial infarction in vitro. Chin. J. Pathophysiol. 2005; 21 [9): 1848-50.
24. Zhang J., Chen J., Liao Y.H. et al. Myocardial autoimmune respons induced by myosin activated T lymphocytes. Chin. J. Cell. And Mol. Immunology 2007; 23[4):343-5.
25. Matsumoto R., Omura Т., Yoshiyama M. et. al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler. Thromb. Vase. Biol. 2005; 25[6): 1168-73.
26. myocardial infarction. Arterioscler. Thromb. Vase. Biol. 2005; 25[6): 1168-73. Kamihata H., Matsubara H., Nishiue T. et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001; 104:1046 -52.
27. Yoon J., Min B.G., Kim Y.H. Differentiation, engraftment and functional effects of pre-treated mesenchymal stem cells in a rat myocardial infarct model. Acta Cardiol. 2005; 60[3): 277-84.
28. Kahn J., BykT., Jansson-Sjostrand L etal. Overexpression of CXCR4on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004; 103: 2942-9.
29. Luttun A., Carmeliet G., Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc. Med. 2002; 12: 88-96.
30. Rafii S., Heissig В., Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 2002; 9: 631 - 41.
31. Szmitko P.E, Fedak P.W, Weisel R.D. et al. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003; 107: 3093-100
32. Kocher A.A., Schuster M.D., Szabolcs M.J. et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 2001;7:430-6.
33. Huss R. Perspectives on the morphology and biology of CD34- negative stem cells. J. Hematother. Stem Cell Res. 2000; 9: 783-93.
34. Tomanek R.J., Schatteman G.C. Angiogenesis: new insights and therapeutic potential. Anat. Rec. 2000; 261:126
35. Davani S., Marandin A., Mersin N. et al. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 2003; 108 Suppl: II 253- 8.
36. Reyes M., LundT., LenvikT. etal. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615-25.
37. Eliopoulos N., Al Khaldi A., Beausejour CM. et al. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther. 2002; 9: 452- 62.
38. Waksman R., Fournadjiev J., Baffour R. etal.Transepicardial autologous bone marrow-derived mononuclear cell therapy in a porcine model of chronically infarcted myocardium. Cardiovasc. Rad. Med. 2004; 5:125-31